ARS Pharmaceuticals (SPRY) has issued an announcement.
ARS Pharmaceuticals, Inc. has updated its corporate presentation for stakeholders and made it available on their website. Additionally, the company received a positive opinion from the European Committee for Medicinal Products for Human Use for its emergency allergy treatment nasal spray, EURneffy, which is now awaiting the European Commission’s decision. However, the company cautions that this is not a guarantee of approval and acknowledges the risks and uncertainties involved in the product’s development, potential market acceptance, and regulatory approval process.
See more insights into SPRY stock on TipRanks’ Stock Analysis page.
